10-Hydroxy-2-decenoic acid

Synonyms: 10-HDA; Queen Bee Acid
10-Hydroxy-2-decenoic acid (10-HDA) 是一种具有多种生理活性的口服不饱和中链脂肪酸,可诱导 A549 细胞中 ROS 介导的细胞凋亡 (apoptosis),抑制 VEGF 诱导的人静脉内皮细胞血管生成,通过激活 AMPK-α 信号通路缓解非酒精性脂肪性肝病 (NAFLD),通过抑制 FFAR4 下游的 NF-κB 信号通路来防止骨质流失,作为一种抗生素对抗多种细菌 (bacteria) 和真菌 (fungi)(例如嗜食脉孢菌、霉菌和金黄色葡萄球菌),对秀丽隐杆线虫具有延年益寿的作用,并通过靶向天冬氨酰 β 羟化酶及抑制软骨细胞衰老来预防骨关节炎。
产品编号: MS-Z27167 纯度: 99.93% CAS No.: 765-01-5 分子式: C10H18O3 分子量: 186.25
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价

产品描述

10-Hydroxy-2-decenoic acid (10-HDA) 是一种具有多种生理活性的口服不饱和中链脂肪酸,可诱导 A549 细胞中 ROS 介导的细胞凋亡 (apoptosis),抑制 VEGF 诱导的人静脉内皮细胞血管生成,通过激活 AMPK-α 信号通路缓解非酒精性脂肪性肝病 (NAFLD),通过抑制 FFAR4 下游的 NF-κB 信号通路来防止骨质流失,作为一种抗生素对抗多种细菌 (bacteria) 和真菌 (fungi)(例如嗜食脉孢菌、霉菌和金黄色葡萄球菌),对秀丽隐杆线虫具有延年益寿的作用,并通过靶向天冬氨酰 β 羟化酶及抑制软骨细胞衰老来预防骨关节炎。

生物实验数据

生物活性 10-Hydroxy-2-decenoic acid (10-HDA) is an orally active unsaturated medium-chain fatty acid with multiple physiological activities that induces ROS-mediated apoptosis in A549 cells, inhibits VEGF-induced angiogenesis in human umbilical vein endothelial cells, alleviates non-alcoholic fatty liver disease (NAFLD) by activating the AMPK-α signaling pathway, prevents bone loss by inhibiting the NF-κB signaling pathway downstream of FFAR4, acts as an antibiotic against various bacteria and fungi (such as Neurospora sitophila, molds, and Staphylococcus aureus), exerts longevity-promoting effects in Caenorhabditis elegans, and prevents osteoarthritis by targeting aspartyl β-hydroxylase and inhibiting chondrocyte senescence.
体外研究
(In Vitro)

10-Hydroxy-2-decenoic acid (0-40 nM,0-6 天) 可促进原代软骨细胞和人 C28/I2 软骨细胞的增殖和合成代谢,同时抑制其凋亡和分解代谢。
10-Hydroxy-2-decenoic acid (0-10 nM,7 天) 可增强人骨关节炎 (OA) 软骨外植体中的软骨细胞合成代谢,并抑制其分解代谢。
10-Hydroxy-2-decenoic acid (0-200 μM, 1-48 小时) 可与 ASPH 结合,并调节 C28/I2 和 HEK-293T 细胞中依赖于 ASPH 的 Asp-Arg-Hydrox 结构域的软骨细胞代谢。
10-Hydroxy-2-decenoic acid (0-10 nM,48 小时) 可降低 C28/I2 细胞中衰老相关的 β-半乳糖苷酶 (SA-β-gal) 以及细胞衰老标志基因 p16 和 p21 的 mRNA 水平。
10-Hydroxy-2-decenoic acid (0-10 nM,48 小时) 通过调节 ASPH-KO C28/I2 细胞中的 ASPH/ERK/p53/p21 和 ASPH/GSK3β/p16 信号通路来抑制软骨细胞衰老。
10-Hydroxy-2-decenoic acid (2 mg/mL) 在低 pH 值条件下对 6C3HED 淋巴肉瘤细胞具有抗肿瘤活性。
10-Hydroxy-2-decenoic acid (50-150 μM) 通过激活 AML12 细胞中的 AMPK-α 来阻止 FFA 诱导的脂质积累和细胞凋亡。
10-Hydroxy-2-decenoic acid (0.07-1.13 mg/mL,24 小时) 通过破坏胞外多糖 (EPS) 结构来降低生物膜的生物量和细胞活力,并抑制金黄色葡萄球菌溶血素的产生。
10-Hydroxy-2-decenoic acid (20-500 μM,11 天) 可降低 HUVECs 细胞和成纤维细胞中 VEGF 诱导的血管形成。
10-Hydroxy-2-decenoic acid (20-500 μM,3 天) 在 500 μM 浓度下可抑制 VEGF 诱导的 HUVEC 细胞增殖,但在 20-100 μM 浓度下不抑制 HUVEC 细胞增殖。
10-Hydroxy-2-decenoic acid (500 μM,24 小时) 可抑制 HUVEC 细胞迁移。
10-Hydroxy-2-decenoic acid (1-100 μM,3-36 h) 抑制 A549、NCI-H460 和 NCI-H23 细胞的生长,IC50 分别为 22.68、44.03 和 44.79 μM,对 IMR90、L-02 和 GES-1 细胞有较弱的细胞毒性。
10-Hydroxy-2-decenoic acid (30 μM,3-24 小时) 通过调控 A549 细胞中的 MAPK、NF-κB 和 STAT3 信号通路,增加 ROS 水平,诱导细胞凋亡。
10-Hydroxy-2-decenoic acid (30 μM,3-24 小时) 通过调控 A549 细胞中细胞周期相关蛋白的表达,诱导细胞周期阻滞。
10-Hydroxy-2-decenoic acid (30 μM,3-24 小时) 通过调节 A549 细胞中的 TGF-β1 信号通路来抑制细胞迁移。
10-Hydroxy-2-decenoic acid (10-100 μM,50 天) 通过独立于 IIS-DAF-16 通路的机制延长 daf-16 (mu86) 突变体和野生型秀丽隐杆线虫的平均和最大寿命。
10-Hydroxy-2-decenoic acid (0.00004-20 mM) 可激活 FFAR4,EC50 为 1.025 mM。
10-Hydroxy-2-decenoic acid (12.5-50 ng/mL,3 天) 通过 FFAR4 受体抑制 NF-κB 信号通路,从而抑制原发性骨髓细胞破骨细胞生成。

RT-PCR

Cell Line: Primary chondrocytes, Human C28/I2 chondrocytes
Concentration: 0 nM, 2 nM, 5 nM, 10 nM, 20 nM, 40 nM
Incubation Time: 0, 2, 4, 6 days
Result: Promoted the mRNA levels of CDK1, CDK2, CDK4, CDK6, cyclin A1, cyclin B1, cyclin D1, cyclin E1, proliferating cell nuclear antigen (PCNA), SRY-box transcription factor 9 (SOX9), COL2 and aggrecan (ACAN).
Inhibited the mRNA levels of COL1A1, COL1A2, COL3A1, α-SMA, FMOD, and FNDC1.
Increased the mRNA levels of CDK1, CDK2, CDK4, CDK6, cyclinA1, cyclinB1, cyclinD1, cyclinE1, and PCNA, SOX9, COL2, and ACAN, while inhibiting the expression of MMP13 and IL6 in the presence of IL-1β (10 ng/mL, 48 h).

Western Blot Analysis

Cell Line: Human OA cartilage explants
Concentration: 0 nM, 5 nM, 10 nM
Incubation Time: 7 days
Result: Upregulated COL2 and ACAN protein levels and downregulated MMP13 protein levels.

RT-PCR

Cell Line: C28/I2 cells
Concentration: 0 nM, 5 nM, 10 nM
Incubation Time: 7 days
Result: Reduced ASPH and COL2 protein levels and increased MMP13 protein levels in knocked down the ASPH expression.

Cell Migration Assay

Cell Line: HUVECs
Concentration: 500 µM
Incubation Time: 24 h
Result: Inhibited cell migration.

Apoptosis Analysis

Cell Line: A549 human lung cancer cells
Concentration: 30 μM
Incubation Time: 3, 24 h
Result: Increased numbers of early and late apoptotic cells, loss of mitochondrial membrane potential (MMP), increased proportion of depolarized cells.
Downregulated Bcl-2, and upregulated BAX, cyto-c, caspase-3, and PARP.
Upregulated p-p38, p-JNK, and I-κB and downregulated p-ERK, p-STAT3, and NF-κB.

Cell Cycle Analysis

Cell Line: A549 human lung cancer cells
Concentration: 30 μM
Incubation Time: 3, 24 h
Result: Increased the percentage of cells in the G0/G1 phase from 62.97% to 80.54%, downregulated AKT, CDK2/4/6, and cyclin D1/E, and upregulated p21 and p27.

Cell Migration Assay

Cell Line: A549 human lung cancer cells
Concentration: 30 μM
Incubation Time: 3, 24 h
Result: Inhibited cell migration, reduced the expression levels of TGF-β1, SNAI1, GSK-3β, N-cadherin and vimentin, and increased the expression level of E-cadherin.

Western Blot Analysis

Cell Line: Primary bone marrow cells
Concentration: 12.5-50 ng/mL
Incubation Time: 3 days
Result: Reduced protein levels of CtsK, TRAP, V-ATPase D2, and MMP9.
Diminished RANKL-induced phosphorylation and the degradation of IκBα.

RT-PCR

Cell Line: Primary bone marrow cells
Concentration: 12.5-50 ng/mL
Incubation Time: 3 days
Result: Had no influence on the expression of Tnfrsf11a (encodes RANK), Csf1r (encodes M-CSFR), Fos, and Mitf. Decreased osteoclastogenesis Nfatc1 and its downstream elements, without affecting the expression of Irf8 and Mafb.
体内研究
(In Vivo)

10-Hydroxy-2-decenoic acid (10 mg/kg,关节腔内注射,每周两次,6 周;100 mg/kg,口服,每周三次,7 周) 在内侧半月板不稳定 (DMM) 小鼠中可促进软骨合成代谢,抑制软骨退化,并缓解手术诱发的膝关节疼痛。
10-Hydroxy-2-decenoic acid (10 mg/kg,关节腔内注射,每周两次,8 周;100 mg/kg,口服,每周三次,8 周) 可缓解自然衰老小鼠的软骨细胞衰老和软骨退化。
10-Hydroxy-2-decenoic acid (0.5-2 mg/mL,皮下注射,一次) 完全抑制了 AKR 小鼠和腹水瘤小鼠的肿瘤发展。
10-Hydroxy-2-decenoic acid (10-50 mg/kg,口服,每日一次,4 周) 对 Methionine (MS-X03991)-Choline (MS-A15337) deficient (MCD) 饮食诱导的 NAFLD 小鼠具有强大的保护作用,可防止脂质积聚和肝损伤,并防止细胞凋亡。
10-Hydroxy-2-decenoic acid (基础日粮中含有1-5 g/kg,口服,21天) 通过抗炎、抗氧化和肠道菌群调节活性减轻了 LPS (MS-X54539) 诱导的肠粘膜损伤鸡模型中的肠道损伤和生长性能损失。
10-Hydroxy-2-decenoic acid (40 mg/kg,口服,每日一次,4 周) 可抑制卵巢切除术 (OVX) 小鼠的破骨细胞骨吸收,而不会影响 OVX 小鼠的骨形成。

Animal Model: DMM mouse (8-week-old male C57BL/6 J) model
Dosage: 10 mg / kg; 100 mg/kg
Administration: IA injection, twice a week for 6 weeks; p.o., three times a week for 7 weeks
Result: Increased the number of chondrocytes, improved knee cartilage erosion and superficial cartilage loss, inhibited cartilage degradation, increased the protein and mRNA levels of Col2 and Acan, and reduced the protein and mRNA levels of Mmp13.
Reduced pain-related behaviors associated with OA and DMM surgery.
Was not associated with any significant toxicity in oral administration group.
Inhibited the OA-induced down-regulation of ASPH expression.
Reduced p16 and p21 protein levels.
Animal Model: Naturally aged (18 months old, male) C57BL/6 J mice model
Dosage: 10  mg/kg; 100 mg/kg
Administration: IA injection, twice a week for 8 weeks; p.o., three times a week for 8 weeks
Result: Reduced knee joint diameter, prevented joint swelling, partially alleviated aging-related cartilage degeneration, and improved OARSI scores.
Reduced p16, p21, and Mmp13 protein levels and increased Col2 protein and ASPH expression.
Animal Model: AKR (2-5 million tumor cells) mice (female mice, 5-6 weeks) model
Dosage: 0.5 mg/mL, 1 mg/mL, 1.5 mg/mL, 2.0 mg/mL, 0.2 mL/mouse
Administration: s.c., once
Result: Had completely prevented the development of transplantable leukemia at 1.5 mg/mL.
Animal Model: Ascitic tumor (the 6CSHED lymphosarcoma, the TAS mammary carcinoma, and the Ehrlich carcinoma, 5-8 million tumor cells) connaught mice (Male mice, 20-22 g) model
Dosage: 0.6 mg/mL, 1 mg/mL, 2.0 mg/mL
Administration: s.c., once
Result: Showed slight activity at a level of 0.6 mg/mL, while conferred complete protection at 1.0 mg/mL.
Animal Model: MCD diet (5 weeks)-induced NAFLD in mice (Male C57BL/6, 6 weeks of age, weighing 20∼25 g) model
Dosage: 10  mg/kg; 50 mg/kg
Administration: p.o., once a day, 4 weeks
Result: Inhibited weight loss, reduced fat droplets, and lowered liver TG by 32% and 60%, respectively.
Reduced hepatocyte vacuoles and ballooning, and attenuated ALT and AST levels.
Reduced TUNEL cell area, reduced BAX expression and increased BCL2 expression.
Was involved in hepatic inflammatory recruitment mainly by regulating the infiltration of macrophages and neutrophils.
Suppressed hepatic lipid accumulation by regulation lipogenesis and fatty acid β-oxidation.
Animal Model: LPS-induced (0.5 mg/kg, i.p.) intestinal mucosal injury chickens (one-day-old male) model
Dosage: 0.1% group, basal diet containing 1 g/kg; 0.5% group, basal diet containing 5 g/kg
Administration: p.o., 21 days
Result: Reduced feed-to-weight ratios in chickens, but had no significant effect on ADFI and ADG.
Alleviated bleeding in the duodenum, jejunum, and ileum, reduced epithelial villous damage in the jejunum and ileum, reduced serum DAO levels and CD in the jejunum, and increased VCR in the jejunum and ileum.
Reduced serum TNF-α, IL-1β, and IL-6 levels, increased serum IgA and IgG concentrations, had no significant effect on TNF-α and IL-1β levels in the 0.5% group, and increased CAT and GSH-px activities in the 0.5% group.
Downregulated the mRNA expression levels of TLR4, NF-κB, IL-1β, IL-6, TNF-α, and Caspase-3, increased Bcl2 expression, and had no significant effect on the mRNA expression levels of TLR4, IL-1β, IL-6, Bax, and Caspase-3 in the 0.5% group, increased expression levels of CAT, SOD2, ZO-1, and OCLN.
Animal Model: OVX mice (Eight-week–old female C57BL6/J) model
Dosage: 40 mg/kg
Administration: p.o., once a day, 4 weeks
Result: Inhibited the serum levels of C-terminal telopeptide of type I collagen (CTX-I) that contributes to osteoclast activity, without altering the serum levels of N-terminal propeptide of type I collagen (PINP).
性状 固体
颜色 White to off-white

化学信息

分子量 186.25
分子式 C10H18O3
CAS No. 765-01-5
别名 10-HDA; Queen Bee Acid

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 250 mg/mL (1342.28 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM5.3691 mL26.8456 mL53.6913 mL134.2282 mL
5 mM1.0738 mL5.3691 mL10.7383 mL26.8456 mL
10 mM0.5369 mL2.6846 mL5.3691 mL13.4228 mL
15 mM0.3579 mL1.7897 mL3.5794 mL8.9485 mL
20 mM0.2685 mL1.3423 mL2.6846 mL6.7114 mL
25 mM0.2148 mL1.0738 mL2.1477 mL5.3691 mL
30 mM0.1790 mL0.8949 mL1.7897 mL4.4743 mL
40 mM0.1342 mL0.6711 mL1.3423 mL3.3557 mL
50 mM0.1074 mL0.5369 mL1.0738 mL2.6846 mL
60 mM0.0895 mL0.4474 mL0.8949 mL2.2371 mL
80 mM0.0671 mL0.3356 mL0.6711 mL1.6779 mL
100 mM0.0537 mL0.2685 mL0.5369 mL1.3423 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

10-羟基-2-癸烯酸 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础